<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30200073</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>17</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1536-5964</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>97</Volume>                    <Issue>36</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Medicine</Title>                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>            </Journal>            <ArticleTitle>Incidental finding of a breast carcinoma on Ga-68-DOTA-1-Nal3-octreotide positron emission tomography/computed tomography performed for the evaluation of a pancreatic neuroendocrine tumor: A case report.</ArticleTitle>            <Pagination>                <MedlinePgn>e11878</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000011878</ELocationID>            <Abstract>                <AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Functional imaging using radiolabeled somatostatin analogues plays an important role in the management of patients with neuroendocrine tumors, and it is a promising tool in the new era of theragnosis and personalized medicine.</AbstractText>                <AbstractText Label="PATIENTS CONCERNS" NlmCategory="UNASSIGNED">The authors present the case of a 63-year-old woman referred for evaluation of a suspected pancreatic neuroendocrine tumor by Ga-68-DOTA-1-Nal3-octreotide positron emission tomography/computed tomography (Ga-68-DOTA-NOC PET/CT).</AbstractText>                <AbstractText Label="DIAGNOSES" NlmCategory="UNASSIGNED">PET/CT confirmed increased uptake of Ga-68-DOTA-NOC in a pancreatic lesion compatible with hyperexpression of somatostatin receptors in a neuroendocrine tumor. Furthermore, PET/CT revealed increased uptake in a breast lesion and in lymphadenomegalies (less intense than in the pancreatic tumor), which conducted to the incidental diagnosis of a breast carcinoma with lymph node metastases.</AbstractText>                <AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">For the breast cancer, the patient underwentneoadjuvant chemotherapy and anti-HER2 monoclonal antibody, after which she was submitted to surgery. Regarding thepancreatic neuroendocrine tumor, it was decided to maintain itunder surveillance.</AbstractText>                <AbstractText Label="OUTCOMES" NlmCategory="RESULTS">Breast carcinomas are known to express somatostatin receptors and this is the first report of Ga-68-DOTA-NOC uptake in a breast tumor.</AbstractText>                <AbstractText Label="LESSONS" NlmCategory="CONCLUSIONS">Ga-68-DOTA-NOC PET/CT could be useful for the management of breast cancer patients in the new era of theragnosis and personalized medicine.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Sampaio Vieira</LastName>                    <ForeName>Tiago</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>HPP - Medicina Molecular SA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Borges Faria</LastName>                    <ForeName>Diogo</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>HPP - Medicina Molecular SA Lenitudes Medical Center &amp; Research.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Souto Moura</LastName>                    <ForeName>Conceição</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>LAP - Laboratório de Anatomia Patológica.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Francisco</LastName>                    <ForeName>Elsa</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Centro Hospitalar de Vila Nova de Gaia/Espinho, Portugal.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Barroso</LastName>                    <ForeName>Sérgio</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>HPP - Medicina Molecular SA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pereira de Oliveira</LastName>                    <ForeName>José</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>HPP - Medicina Molecular SA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D002363">Case Reports</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Medicine (Baltimore)</MedlineTA>            <NlmUniqueID>2985248R</NlmUniqueID>            <ISSNLinking>0025-7974</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C504894">68Ga-DOTANOC</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D009942">Organometallic Compounds</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>AIM</CitationSubset>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Nuklearmedizin. 2008;47(6):261-5</RefSource>                <PMID Version="1">19057800</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nucl Med. 2014 Feb;55(2):177-80</RefSource>                <PMID Version="1">24434288</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nucl Med. 2013 Mar;54(3):364-72</RefSource>                <PMID Version="1">23297077</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Nucl Med. 2017 Jun;42(6):e313-e316</RefSource>                <PMID Version="1">28240663</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nucl Med. 2015 Jan;56(1):98-105</RefSource>                <PMID Version="1">25525181</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Clin Oncol. 2017 Dec;14(12):749-762</RefSource>                <PMID Version="1">28975929</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nucl Med. 2015 Sep;56(9):1447-52</RefSource>                <PMID Version="1">26159585</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nucl Med. 2016 Dec;57(12):1949-1956</RefSource>                <PMID Version="1">27811124</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2005 Jul;92(2):175-86</RefSource>                <PMID Version="1">15986128</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocr Relat Cancer. 2010 Jan 29;17(1):R53-73</RefSource>                <PMID Version="1">19995807</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Tumour Biol. 2017 Oct;39(10):1010428317728285</RefSource>                <PMID Version="1">29025377</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>ScientificWorldJournal. 2014 Feb 13;2014:194123</RefSource>                <PMID Version="1">24693229</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anticancer Res. 2013 Aug;33(8):3015-9</RefSource>                <PMID Version="1">23898054</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Mol Sci. 2017 Jan 26;18(2):</RefSource>                <PMID Version="1">28134770</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Future Oncol. 2014 Nov;10(14):2259-77</RefSource>                <PMID Version="1">25471038</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002277" MajorTopicYN="N">Carcinoma</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D033162" MajorTopicYN="N">Incidental Findings</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000072281" MajorTopicYN="N">Lymphadenopathy</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018358" MajorTopicYN="N">Neuroendocrine Tumors</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009942" MajorTopicYN="Y">Organometallic Compounds</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000072078" MajorTopicYN="Y">Positron Emission Tomography Computed Tomography</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019275" MajorTopicYN="Y">Radiopharmaceuticals</DescriptorName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30200073</ArticleId>            <ArticleId IdType="doi">10.1097/MD.0000000000011878</ArticleId>            <ArticleId IdType="pii">00005792-201809070-00015</ArticleId>            <ArticleId IdType="pmc">PMC6133576</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>